Home›Stock Screener›Ishita Drugs & Indus

Ishita Drugs & Indus Share Price Today | Stock Price & Ishita Drugs & Indus Share Screener

ISHITADR Pharmaceuticals & Biotechnology
Live Share Price BSE
₹78.50
▲ 5.78 (7.95%)
2026-11-19 00:00:00

As of November 19, 2026, the live Ishita Drugs & Indus share price (BSE: ISHITADR) is ₹78.50, up 7.95% from the previous close, with shares trading between ₹78.50 and ₹83.00 in today's trading session, and a 52-week range of ₹67.60–₹83.57. Track ISHITADR market value to gauge the company's total market size. Use the Ishita Drugs & Indus stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Ishita Drugs & Indus opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹13 and net income of ₹1, with EBITDA of ₹1, an operating margin of 6.0% and a profit margin of 7.7%.

Ishita Drugs & Indus Market Cap ₹21.71 Cr.
ISHITADR P/E Ratio (TTM) 30.00
Ishita Drugs & Indus P/B Ratio 1.82
EPS (TTM) ₹2.60
Dividend Yield -
Debt to Equity 0.18
ISHITADR 52 Week High ₹83.57
Ishita Drugs & Indus 52 Week Low ₹67.60
Operating Margin 6.00%
Profit Margin 7.69%
ISHITADR Revenue (TTM) ₹13.00
EBITDA ₹1.00
Net Income ₹1.00
Total Assets ₹13.00
Total Equity ₹12.00

Ishita Drugs & Indus Share Price Chart

Track the current stock price of Ishita Drugs & Indus with an interactive chart. Analyse ISHITADR share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Ishita Drugs & Indus stock quote in one place.

The quote of ₹78.50 sits between the 52-week low of ₹67.60 and the 52-week high of ₹83.57, and the latest session moved 7.95% from the previous close.

Ishita Drugs & Indus Company Profile - Fundamental Screener

Screen Ishita Drugs & Indus company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ISHITADR shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE806D01016.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE806D01016

Ishita Drugs & Indus Balance Sheet Screener

Screen ISHITADR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹13, down from ₹16 in 2025.

Latest statistics put total assets at ₹13 and shareholder funds at ₹12, with a leverage ratio of 0.18.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 13 16 11 11 11 9 10 8 7 7
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 1 1 1 1 1 1 1 1 1 1

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 0 0 0 0 0 0 0 0 0 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 12 11 10 9 9 8 7 6 6 6
Share Capital 3 3 3 3 3 3 3 3 3 3
Reserves & Surplus 9 8 7 6 6 5 4 3 3 3

Ishita Drugs & Indus Income Statement Screener - Profit & Revenue Analysis

Screen Ishita Drugs & Indus income statement and profit fundamentals. Analyze ISHITADR quarterly results. Ishita Drugs & Indus reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹13 and net profit was ₹1, equal to earnings per unit of ₹2.40, at an operating margin of 6%.

In that period expenses were ₹12, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹15 and net profit of ₹1.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 13 15 15 16 12 14 14 15 9 7 7 7 8
Expenses 12 14 14 14 11 13 13 14 9 6 6 7 7

Operating Costs and Margins

EBITDA 1 1 1 1 1 1 1 1 1 1 0 0 1
Operating Profit % 6.00% 5.00% 7.00% 6.00% 6.00% 8.00% 7.00% 5.00% 6.00% 7.00% 6.00% 4.00% 4.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 1 1 1 1 1 1 1 1 1 0 0 0 0
Tax 0 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 1 1 1 1 1 1 1 1 0 0 0 0 0
EPS 2.40 2.60 2.90 2.50 1.93 2.69 2.77 1.83 1.18 0.83 0.61 0.46 0.74

Ishita Drugs & Indus Cash Flow Screener - Liquidity Fundamentals

Screen ISHITADR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹4, and net cash flow was an outflow of ₹2.

Over the same period, investing activities used ₹2 and financing activities used ₹4.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 4 -4 2 -3 3 -1 1 1 1 1
Investing Activities -2 -1 0 1 -1 3 -1 -1 -1 -1

Financing and Net Cash

Financing Activities -4 4 -1 1 0 0 0 0 0 -1
Net Cash Flow -2 0 1 -1 2 2 0 0 0 -1

Ishita Drugs & Indus Shareholding Pattern Screener

See Ishita Drugs & Indus shareholding pattern with promoter, FII, and DII holdings. Check Ishita Drugs & Indus promoter holding and ownership changes for ISHITADR on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 50.04%, foreign institutions 0.00%, domestic institutions 0.00% and the public 48.33%, spread across 5,105 shareholders.

The shareholder count was 5,105 in 2026-Sept, compared with 5,146 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 50.04% 50.04% 50.04% 50.04% 49.96% 49.92% 49.91% 49.85%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 48.33% 47.89% 47.37% 46.33% 46.63% 46.76% 46.89% 46.89%
Other Holding 1.63% 2.07% 2.60% 3.63% 3.42% 3.33% 3.20% 3.27%
Shareholder Count 5,105 5,146 5,194 5,263 5,320 5,341 5,398 5,412

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Ishita Drugs & Indus. Ishita Drugs & Indus dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Ishita Drugs & Indus.

Ishita Drugs & Indus Stock Index Membership - Nifty & Sensex

See which indices include Ishita Drugs & Indus stock. Check ISHITADR index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Ishita Drugs & Indus is not part of any tracked indices.
Only major market indices are tracked in our system.

Ishita Drugs & Indus Market Events Screener - Corporate Actions

Get Ishita Drugs & Indus corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Ishita Drugs & Indus stock events that may affect ISHITADR share price, along with derivatives, futures and options activity and sector gainers.

12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 3, 2026, with a record date of November 3, 2026.

It is followed by Annual General Meeting dated September 30, 2026 and Quarterly Result Announcement dated August 8, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-03 2026-11-03 Quarterly Result Announcement NA 2.08%
2026-09-30 2026-09-30 Annual General Meeting NA -0.28%
2026-08-08 2026-08-08 Quarterly Result Announcement NA -1.20%
2026-05-30 2026-05-30 Quarterly Result Announcement NA -2.87%
2026-02-07 2026-02-07 Quarterly Result Announcement NA 6.73%
2025-11-11 2025-11-11 Quarterly Result Announcement NA -0.40%
2025-09-29 2025-09-29 Annual General Meeting NA 8.66%
2025-08-12 2025-08-12 Quarterly Result Announcement NA -9.29%
2025-05-30 2025-05-30 Quarterly Result Announcement NA -2.94%
2025-02-13 2025-02-13 Quarterly Result Announcement NA -12.35%
2024-11-12 2024-11-12 Quarterly Result Announcement NA 1.31%
2024-09-30 2024-09-30 Annual General Meeting NA -3.22%

Ishita Drugs & Indus Competitors Screener - Peer Stocks Comparison

Screen ISHITADR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,075 41.20 61,674 12.69% 11,565 63.60
Divis Laboratories 303,749 90.40 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 177,632 85.50 13,886 20.34% 2,138 47.27
Laurus Labs 130,972 97.10 6,868 22.01% 890 69.60
Zydus Life Science 118,693 28.00 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,186 42.00 35,059 3.90% 4,158 70.24
Cipla 112,438 39.90 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.10 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,903 26.00 34,145 5.56% 3,503 66.06
Lupin 90,557 17.60 29,039 26.75% 5,356 44.92

Ishita Drugs & Indus Company Announcements - News & Reports Screener

Screen ISHITADR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 3, 2026.

The next most recent announcements are dated November 3, 2026 and October 28, 2026.

Date Update Actions
2026-11-03 Outcome Of Board Meeting Held On 03Rd November 2026 -
2026-11-03 Board Meeting Outcome for Outcome Of Board Meeting Held On 03Rd November 2026 -
2026-10-28 Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 For The Quarter Ended 30Th September 2026 -
2026-10-13 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-02 Announcement under Regulation 30 (LODR)-Change in Management -
2026-10-02 Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s -
2026-10-02 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-26 Closure of Trading Window -
2026-09-22 Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Availing Credit Facilities From Bank -
2026-09-22 Board Meeting Outcome for Outcome Of Board Meeting Held On 22Nd September 2026 -
2026-09-18 Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-08-31 Weblink Intimation Letter To The Shareholders -
2026-08-27 Reg. 34 (1) Annual Report. -
2026-08-27 NOTICE OF 33RD ANNUAL GENERAL MEETING (AGM) ALONG WITH THE E-VOTING PERIOD -
2026-08-27 INTIMATION OF E- VOTING AS PER THE REGULATION 44 OF SEBI (LODR) REGULATION 2015 -
2026-08-27 INTIMATION ABOUT THE BOOK CLOSURE FOR 33RD ANNUAL GENERAL MEETING (AGM) -
2026-08-08 Announcement under Regulation 30 (LODR)-Change in Management -
2026-08-08 Outcome Of Board Meeting Held On 08H August 2026 -
2026-08-08 Board Meeting Outcome for Outcome Of Board Meeting Held On 08Th August 2026 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹78.50, within a 52-week range of ₹67.60 to ₹83.57. The P/E ratio is 30.00 and the P/B ratio is 1.82, with earnings per unit of ₹2.60. Market capitalisation stands at ₹21.71 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.